Canada: Intellectual Property Weekly Abstracts Bulletin — Week Of October 2, 2017

Last Updated: October 5 2017
Article by Chantal Saunders, Beverley Moore, Adrian J. Howard and Jillian Brenner

Most Read Contributor in Canada, October 2017

Patent Decisions

Order of prohibition granted in respect of crystalline form I ODV Succinate
Pfizer Canada Inc. v. Apotex Inc., 2017 FC 774

Drug: PRISTIQ o-desmethyl-venlafaxine ("ODV")

This is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations. The Court began by noting a related decision in which a different second person sent a separate Notice of Allegation making different allegations. The Court issued an order of prohibition.

The patent relates to Form I ODV succinate, which the Court accepted is a novel composition of matter. Venlafaxine metabolizes into ODV, and was previously patented and approved to treat depression. The Court set out the invention story, including the experimentation with ODV fumarate and forming a pro-drug.

There were several disputes relating to claim construction, which the Court addressed and then found that Apotex's allegation of non-infringement was not justified, although some claims were not infringed by all Apotex's products. In terms of obviousness, the allegation was found not to be justified on the basis of a detailed analysis finding that, although "the new composition of matter being the crystalline Form I ODV succinate, was 'worth a try'", and "there were 'possibilities' that the Skilled Person would find the invention", this was not sufficient. With respect to utility, the Court had asked the parties for submissions in light of the Supreme Court of Canada decision in AstraZeneca v Apotex. The Court then indicated that it was applying the approach set out in that decision, proceeding on a claim by claim basis having regard to its previous construction of the claims.

The Court also addressed an argument made by Apotex relating to "overpromising" in relation to subsection 27(3) of the Patent Act. The Court noted:

I also observe that the alleged overpromises resemble the promise arguments advanced by Apotex, which are no longer valid having regard to AstraZeneca. If the Supreme Court intended to say, in effect, that the Promise Doctrine was not good law in terms of utility under s. 2, but was good law in terms of patent specifications under subsection 27(3) it could have done so; it did not.

The Court concluded by finding that the specification analysis pursuant to section 27(3) requires the patentee to define the precise extent of the exclusive property claimed. In terms of anticipation, although it filed evidence, Pfizer did not address anticipation in its memorandum of fact and law, arguing that Apotex had not filed evidence in this regard. The sections of the expert evidence that Apotex pointed to were submitted in respect of obviousness not anticipation, and no instructions relating to anticipation were given to Apotex's experts. The Court did not accept Apotex's arguments that it could rely on this evidence. However, the Court also did not agree that Pfizer could split its case by failing to deal with anticipation in its memorandum but addressing it in oral reply at the end of the hearing. The Court held that Pfizer could not proceed on the basis that anticipation was not in issue once Apotex filed its memorandum dealing with anticipation. The Court did not accept Apotex's expert evidence on anticipation. The Court also refused to accept Apotex's argument that its allegations of anticipation in its NOA were sufficient to displace the statutory presumption of validity. The presumption of validity was found to prevail in this case and the allegation of anticipation not justified. The Court also found Apotex's allegation of double patenting not to be justified. Costs were awarded to Pfizer.

Judicial review of the Minister of Health's decision to cancel reconsideration of abbreviated new drug submission dismissed
Apotex Inc. v. Canada (Health), 2017 FC 857

The Court dismissed Apotex's judicial review of the Minister of Health's decision to cancel the reconsideration of Apotex's submission in respect of its Apo-Omeprazole tablets. The underlying facts of this decision span a period of over ten years, in which Apotex had sought approval for its Apo-Omeprazole tablets. A brief overview of some of the background facts are as follows.

In 2003, the examination of Apotex's submission was understood to have been completed but placed on patent hold. In 2008, Health Canada revoked approval because Apotex's abbreviated new drug submission ("ANDS") lacked a study showing bioequivalence to the Canadian reference product ("CRP") when the drug is taken with a high calorie/high fat meal. Apotex chose to challenge the Minister's decision but was unsuccessful before the Federal Court and Federal Court of Appeal. In 2013, Apotex refiled its ANDS and included its 15-year old high calorie/high fat study, but the Minister refused to issue a NOC because she was not satisfied with the results of the study and the study design. In 2015, Apotex pursued a reconsideration process offered by Health Canada. In Apotex's view, the reconsideration exercise ought to be about whether or not its new drug is safe and effective, whereas the Minister contends that the manufacturer of a new drug may file an ANDS that compares the CRP, such that the new drug is bioequivalent, based on the pharmaceutical and, when the Minister considers it necessary, bioavailability characteristics. Despite an exchange of correspondence about suggested questions for the reconsideration, the parties could not agree on a proper question to put to an external expert panel. The Director General ultimately refused reconsideration.

In its application for judicial review, Apotex raised two arguments: 1) the Minister fettered her discretion in deciding that the reconsideration exercise had to focus on bioequivalence instead of allowing it to establish safety and efficacy; and 2) the Minister had created expectations that she would follow a procedure that included working with a sponsor to draft the questions to be posed to the Reconsideration Panel that would address the issues in dispute.

The Court first reviewed the doctrine of legitimate expectations. The Court noted that Apotex's position treated the reconsideration process as an appeal any issue, including the issue of the safety and effectiveness of a new drug, using the short cut that is the ANDS. The Court concluded that this was not a legitimate expectation about procedure or practice that is clear, unambiguous and unqualified. Rather, the Court found that the reconsideration policy did not allow Apotex to circumvent the requirement for bioequivalence found in the Food and Drug Regulations ("Regulations").

The Court also found that there was no was fettering of discretion. While it was completely clear what discretion was alleged to have been fettered, the Court concluded that there was no evidence that the Minister fettered her discretion through strict adherence to the guidelines. Rather, the Court found that the Minister did precisely what the Regulations required of her and focused the question on bioequivalence instead of safety and effectiveness. The Court also found that if the fettering was that the Minister had to agree to a question, the Minister would have had to have that discretion in the first place, which she did not. The Court concluded that a reconsideration exercise that would exclude bioequivalence in favour of safety and effectiveness, as argued for by Apotex, would be outside of the framework of the Regulations.

Patent Related Decisions

Motion for a protective order drafted and agreed to by the parties dismissed
Live Face on Web, LLC v. Soldan Fence and Metals (2009) Ltd., 2017 FC 858

The Court dismissed the parties' motion for a protective order. The underlying dispute is a patent infringement action and the Plaintiff made an informal motion for the issuance of a protective on consent of the Defendant. In dismissing the motion, the Court concluded:

[...] absent highly unusual circumstances, it is not necessary for the Court to incorporate in an order the specific or additional protective measures agreed by the parties for them to be effective, and that the Court ought no longer to routinely issue protective orders on consent of the parties.

The Court added that the majority of the provisions from typical protective orders are already covered by the common law doctrine of the implied undertaking rule. The Court dismissed the parties' arguments that the proposed order is necessary despite the existence of the implied undertaking rule. Specifically, the parties argued that the proposed order expanded on the rule in two ways: 1) it limits the number of individuals that may access the information; and 2) it provides that parties must give each other prior notice of their intention to file material in Court, to allow the disclosing party an opportunity to seek a confidentiality order to ensure the continued protection of the information.

In respect of the first argument, the Court noted that a breach of these limits will not necessarily constitute an improper use of discovery evidence, and that it was certainly not obvious that it should be punishable by contempt. In respect of the second argument, the Court agreed that such a provision was unquestionably useful. However, the Court did not consider that its incorporation into an order of the Court was necessary for it to be fully effective. The Court noted that it could not "conceive that anyone would think that a solicitor could, with impunity, breach such an undertaking simply because it has not been made part of an order of the Court".

The Court also dismissed the notion that that in the absence of a protective order, a separate agreement is needed to bind third parties to the implied undertaking rule. The Court found that this notion was simply incorrect in law.

Motion to amend in light of SCC's decision in AstraZeneca allowed in part; amendments for allegation of fraud without particular facts dismissed
Apotex Inc. v. Shire LLC, 2017 FC 831

In this motion, Apotex sought to amend its statement of claim in light of the Supreme Court's decision in AstraZeneca Canada Inc. v Apotex Inc., 2017 SCC 36. The Court found that the majority of the amendments proposed by Apotex did not introduce new facts, but simply "recast" the same factual allegations underlying Apotex's inutility plea. In describing the proposed amendments, the Court noted that:

[...] The amendments are slipshod, inconsistent and confusing. Although Apotex portrays its amendments as being made in accordance with the Supreme Court's teachings on the correct approach to utility, they reflect, in my view, an obtuse application of selected passages of the Supreme Court's decision, a refusal to come to terms with and embrace the essence of the Supreme Court's teachings, and a fairly desperate attempt to shoehorn Apotex's promise allegations into each and every ground of invalidity known to law. The resulting pleading remains haunted by the ghost of the now defunct promise doctrine and is neither particularly helpful nor illuminating.

Notwithstanding the foregoing, the Court concluded that the factual allegations of the statement of claim relating to inutility should not be struck as disclosing no reasonable cause of action.

The Court also allowed Apotex's proposed amendments that alleged new facts, with the exception of the amendments found to be "a bare pleading that "the applicant was aware" that the inventors had not demonstrated or had no sound basis to predict a particular utility". The Court noted that pleadings of fraud are a serious matter and the proposed pleading contained no particular facts upon which a Court might find any particular state of mind or knowledge in any particular persons at any particular time.

Appeal of order adjourning applicant's motion for confidentiality order dismissed
Innovator Company v. Canada (Attorney General), 2017 FC 864

The Court dismissed the appeal of the Prothonotary's Order adjourning the Applicant's motion for a confidentiality order until after such time that the Other Innovator is served with the Notice of Application, among other things. The underlying proceeding is an application seeking judicial review of the Minister's decision requiring that the Applicant address patents listed against the Other Innovator's product. The Prothonotary had found that the Other Innovator is a person directly affected by the order sought in the underlying application, and that it ought to have been named as a Respondent.

Copyright Decision

Copyright in registered plans of survey belongs to the Crown
Keatley Surveying Ltd. v. Teranet Inc., 2017 ONCA 748

Land surveyors brought a class action alleging copyright infringement through the digitizing, storing and copying of the plans of survey created by the surveyors and registered in Ontario's electronic land registry system, Teranet.

Teranet sought summary judgment on the issue of the impact of registration or deposit of plans of survey under the Teranet system on Crown copyright as described in section 12 of the Copyright Act. The motion judge held that copyright in the plans of survey registered or deposited under the ELRS belonged to the Province of Ontario, and not to the surveyor who created the plan.

The Ontario Court of Appeal has upheld the decision of the motion judge, albeit from a slightly different reasoning.

The Court recognized copyright in plans of survey, noted they are artistic works, and the land surveyor is the author of said work. The Court further noted that surveyors do not have to register a plan with the province of Ontario, and that there are measures that can be taken to prevent that from happening. However, the Court did state that if the surveyor owned copyright then there is a breach of copyright regardless of whether a government employee or a third-party retained by the government makes a copy.

After reviewing the whole of the statutory scheme for plans of survey, the Court held that the Crown has complete control over registered or deposited plans of survey and complete control over the "publication" of those plans of survey within the meaning of the Copyright Act. However, the Court did not find that the legislation transfers "ownership" of the copyright to Ontario. Instead, Ontario's publishing of plans of survey, making those copies available to the public, is done under the "direction or control of Her Majesty", thus section 12 of the Copyright Act provides that copyright in the registered plans of survey belongs to the Crown.

On this basis, the decision on summary judgment to dismiss the class proceeding was upheld.

Industry Update

Health Canada released a Notice: Consultation on proposals for prescription drug transparency. The website indicates that the consultation is available online between September 28, 2017, and October 28, 2017, and that feedback is to be submitted exclusively through the consultation document.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.